Association of CD44−/CD24− Breast Cancer Cells with Late Stage Tumor Recurrence

Xinbo Qiao,Yixiao Zhang,Lisha Sun,Qingtian Ma,Jie Yang,Liping Ai,Jinqi Xue,Guanglei Chen,Hao Zhang,Ce Ji,Xi Gu,Haixin Lei,Yongliang Yang,Caigang Liu

DOI: https://doi.org/10.1101/2020.12.07.414599

2020-01-01

Abstract:Tumor metastasis remains the main cause of breast cancer-related deaths, especially the later breast cancer distant metastasis. This study assessed CD44−/CD24− tumor cells in 576 tissue specimens for associations with clinicopathological features and metastasis and then investigated the underlying molecular events. The data showed that level of CD44−/CD24− cells was associated with later postoperative distant tumor metastasis. Furthermore, CD44−/CD24− triple negative cells could spontaneously convert into CD44+/CD24− cancer stem cells (CSCs) with properties similar to CD44+/CD24− CSCs from parental MDA-MB-231 cells in terms of gene expression, tumor cell xenograft formation, and lung metastasis in vitro and in vivo . Single-cell RNA sequencing identified RHBDL2 as a regulator that enhanced spontaneous CD44+/CD24− CSC conversion, whereas knockdown of RHBDL2 expression inhibited YAP/NF-κB signaling and blocked spontaneous CD44−/CD24− cell conversion to CSCs. These data suggested that the level of CD44−/CD24− tumor cells could predict breast cancer prognosis, metastasis, and response to adjuvant therapy.